Want to see NL:LKFT full AI Analyst Report?
LKFT Stock Chart & Stats
€24.50
€0.24(0.98%)
At close: 4:00 PM EDT
€24.50
€0.24(0.98%)
Day’s Range― - ―
52-Week Range€22.32 - €32.74
Previous CloseN/A
Volume59.04K
Average Volume (3M)132.01K
Market Cap
€1.68B
Enterprise Value-€394.90
Total Cash (Recent Filing)€2.98B
Total Debt (Recent Filing)€6.43M
Price to Earnings (P/E)3.3
Beta0.67
Next Earnings
Nov 12, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.39
Shares Outstanding65,897,070
10 Day Avg. Volume76,560
30 Day Avg. Volume132,014
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.00Price Target Upside-10.20% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)-3.01
Revenue Forecast (FY)€29.89M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage gives Galapagos substantial financial resilience and flexibility to fund research, partnerships, or restructuring without depending heavily on external borrowing.
Improved ProfitabilityThe shift from prior losses to strong TTM profitability indicates improved earnings power and provides a stronger operating foundation, although sustaining these results remains important.
High Gross MarginsConsistently high gross margins suggest a favorable revenue mix and strong economics on recognized revenue, which can support durable profitability if the company maintains product and partnership quality.
Bears Say
Persistent Cash BurnNegative operating and free cash flow in every reported period means the business is not currently self-funding. Continued cash consumption could reduce financial flexibility despite the strong balance sheet.
Uneven Revenue MomentumThe recent revenue decline following a sharp prior increase points to an unpredictable top-line trajectory, making it harder to assess the durability of growth and future operating leverage.
Earnings VolatilityThe history of significant earnings swings indicates that current profitability may be sensitive to product mix, milestones, or other irregular items, creating uncertainty around sustainable returns.
Galapagos News
LKFT FAQ
What was Galapagos’s price range in the past 12 months?
Galapagos lowest stock price was €22.32 and its highest was €32.74 in the past 12 months.
What is Galapagos’s market cap?
Galapagos’s market cap is €1.68B.
When is Galapagos’s upcoming earnings report date?
Galapagos’s upcoming earnings report date is Nov 12, 2026 which is in 83 days.
How were Galapagos’s earnings last quarter?
Galapagos released its earnings results on Aug 10, 2026. The company reported €0.029 earnings per share for the quarter, beating the consensus estimate of -€0.123 by €0.152.
Is Galapagos overvalued?
According to Wall Street analysts Galapagos’s price is currently Overvalued.
Does Galapagos pay dividends?
Galapagos does not currently pay dividends.
What is Galapagos’s EPS estimate?
Galapagos’s EPS estimate is -0.7.
How many shares outstanding does Galapagos have?
Galapagos has 65,897,070 shares outstanding.
What happened to Galapagos’s price movement after its last earnings report?
Galapagos reported an EPS of €0.029 in its last earnings report, beating expectations of -€0.123. Following the earnings report the stock price went up 3.84%.
Which hedge fund is a major shareholder of Galapagos?
Currently, no hedge funds are holding shares in NL:LKFT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galapagos
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
LKFT Stock 12 Month Forecast
Average Price Target
€22.00
▼(-10.20% Downside)